Physician profile
Christopher Patrick Herrington
NPI 1598932139
$3,472.24
in general payments reported to CMS, 2019-2025
29 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $294 · 2021: $355 · 2022: $417 · 2023: $485 · 2024: $666 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.91 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.74 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $487.06 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $297.53 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $228.41 | 2019-2025 | |
| Gilead Sciences, INC. | $206.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.10 | 2019-2025 | Relistor, Trulance, Xifaxan |
| Celgene Corporation | $164.10 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $139.08 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $99.39 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $82.02 | 2024-2025 | |
| Madrigal Pharmaceuticals | $71.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $68.33 | 2020-2022 | |
| Celltrion USA INC. | $54.62 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $49.53 | 2020-2023 | Linzess |
| Romark Laboratories, Lc | $35.29 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.33 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $31.26 | 2021-2023 | |
| Braintree Laboratories, INC. | $27.90 | 2021-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $27.63 | 2020-2022 | |
| Shield Therapeutics INC | $20.21 | 2023 | Accrufer |
| Fresenius Kabi USA, LLC | $19.76 | 2023 | Idacio |
| Novo Nordisk INC | $17.83 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $16.91 | 2025 | Zenpep |
| Concordia Pharmaceuticals INC. | $16.29 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.88 | 2025 | Givlaari |
| Lilly USA, LLC | $14.67 | 2024 | Omvoh |
| Biocon Biologics INC | $14.26 | 2025 | Yesintek |
| Merck Sharp & Dohme LLC | $13.78 | 2024 | Dificid |
| Allergan, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Herrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.